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Background: A subset of patients with ductal carcinoma in situ (DCIS) will develop invasive breast cancer (IBC). To
date, there are no effective predictive biomarkers for identifying this subset with worse prognosis whose lesions are
essentially indistinguishable histologically from those with favorable outcomes. We hypothesized that measurable
parameters that discriminate DCIS from DCIS with concurrent invasion may serve as diagnostic biomarkers (BM) of
progressive cancer in situ (CIS).
Results: Using a novel imaging-based method of tissue testing, we measured the relative expression levels of three
candidate BM proteins specifically implicated in IBC progression - the insulin-like growth factor I receptor (IGF-IR),
Ras-related protein 1 (Rap1), and Vav2 oncoprotein. Protein profiles were compared in 42 histologically normal
mammary epithelial samples, 71 CIS (35 without/36 with invasion either on diagnostic biopsy or final surgical
excision), and 98 IBC of known estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth
factor receptor 2 (HER2) status. The levels of the IGF-IR and Rap1 protein expression were significantly elevated in
ER-positive (ER+/PR+/−/HER2 –) DCIS relative to normal epithelium (P <0.0001). The IGF-IR protein expression was
also significantly up regulated in HER2-positive (ER+/−/PR+/−/HER2+) DCIS relative to normal epithelium (P = 0.0002).
IGF-IR and Rap1 protein expression levels were similar among DCIS patients without or with concurrent invasion. Vav2
upregulation in DCIS relative to normal group was not associated with steroid hormone receptor and HER2 status, but
was associated with the presence of concurrent invasion, including microinvasion (invasive foci of less than 1 mm).
DCIS with high Vav2 were more than twice as likely to progress to invasive cancers as DCIS with low Vav2 (odds ratio,
2.42; 95% CI, 1.26-4-65; P =0.008). Furthermore, a receiver operating characteristic curve analysis revealed moderate
ability of Vav2 protein expression measurements in DCIS to predict the existence of invasion concurrent with DCIS
(area under the curve, 0.71; 95% CI, 0.59- 0.84).
Conclusions: Our novel findings hold promise for utilizing Vav2 protein as a predictive BM for differentiating progressive
from non-progressive DCIS.
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Ductal carcinoma in situ (DCIS) of the breast is a nonin-
vasive lesion most commonly detected in asymptomatic
women as a small area of abnormal calcification on
mammography. Incidence of DCIS has risen rapidly over
the past decades largely due to increased mammography
screening [1]. Currently, DCIS accounts for nearly one-
fourth of all new breast cancer (BC) diagnoses, with* Correspondence: guvakova@mail.med.upenn.edu
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unless otherwise stated.more than 1 million women in the United States pro-
jected to be diagnosed with DCIS by 2020. Routine
screening cannot reliably distinguish progressive and in-
dolent DCIS. Hence, although surgery is still considered
the standard treatment for patients diagnosed with
DCIS, there has been considerable debate in clinical
practice regarding the classification of these lesions [2].
To date, little is known about molecular biomarkers
(BM) that may help to determine the likelihood that
DCIS identified on diagnostic biopsy would remain con-
tained in situ or become invasive [3]. The hallmark of
progressive tumors is the abnormal migratory propertiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Normala 42 (100%) 55.6 (53) 29-85
CIS without invasion 35 (100%) 56.0 (58) 35-80
DCIS 34 (97.1%) 56.1 (58) 35-80
LCIS 1 (2.9%) 52.0 (52) 52-52
CIS with invasion 36 (100%) 54.1 (55) 29-74
DCIS/T1mic 11 (30.6%) 54.5 (55) 38-74
DCIS/IDC 21 (58.3%) 53.3 (55) 29-72
LCIS/ILC 4(11.1%) 57.0 (59) 47-63
IBC 98 (100%) 57.8 (57) 28-88
IDC 76 (77.5%) 56.4 (56) 28-88
ILC 22 (22.5%) 62.6 (62) 32-87
aHistologically normal breast epithelium from patients with breast cancer.
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original tumor site. Our candidate BMs, the insulin-like
growth factor I receptor (IGF-IR), Ras-related protein 1
(Rap1), and oncoprotein Vav2, are molecules whose up-
regulation have been implicated in promoting the aggres-
sive behavior of cancer cells in preclinical models [4-6].
As the key receptor in cancer cell proliferation and mi-
gration, IGF-IR has become one of the most intensively
investigated molecular targets in oncology [4-6]. In our
previous studies, the concurrent up-regulation of the
IGF-IR and the small GTPase Rap1 in primary BC sug-
gested the involvement of both proteins in the etiology
of the disease [7]. Rap1 is highly homologous to the
small GTPase Ras, whose oncogenic form plays a critical
role in promoting cancers [8,9]. Although oncogenic
mutations of Rap1 have not been found, Rap1 deregula-
tion in cancer may occur following abnormal regulation
of the hormone, growth factor, and/or cytokine receptors
[10-12]. In the human BC model, hyperactivation of
Rap1 was related to loss of mammary epithelial cell po-
larity, cell invasion in vitro and tumorigenicity in nude
mice [13]. Our biochemical studies showed that down-
stream inputs from the activated IGF-IR to Rap1 pro-
moted BC cell migration [14]. Hence, we hypothesized
that up-regulation of IGF-IR/Rap1 may increase the pro-
pensity of DCIS transitioning to IBC.
The overexpression of oncoprotein Vav2 has been im-
plicated in advanced metastatic breast cancer [15]. As a
member of the Vav guanine nucleotide exchange factor
family of oncogenes, Vav2 activates the small Rho family
GTPases (RhoA, Rac, Cdc42) that may promote cell mi-
gration by altering cell morphology and gene expression
[16]. The Vav2 protein acts downstream of a myriad of
cell surface receptors, many of which are overexpressed
already in precancers and therefore may activate Vav2 to
drive cancer progression [17]. Despite literature impli-
cating a potential role of Vav2 protein in IBC progres-
sion, studies on human tissue supporting this hypothesis
are largely missing.
In this study, we applied our imaging-based analytic
tools to accurately quantify, on continuous-scale levels,
three candidate BM proteins in biopsy and surgical spec-
imens from 144 patients diagnosed with BC. We based
our study on 42 histologically normal mammary epithe-
lial samples from patients with BC, 71 CIS (35 without/
36 with invasion either on diagnostic core needle biopsy
(CNB) or final surgical excision), and 98 IBC with the
aim of identifying associations between protein expres-
sion in DCIS and the presence of invasion concurrent
with DCIS. We provide updated results for IGF-IR and
Rap1, making the conclusions considerably more defini-
tive. In addition, we describe novel results for Vav2 pro-
tein, whose protein expression in early stage breast
cancer had not been investigated.Materials and methods
Patient samples
211 breast specimens, collected from patients who had
surgical excision for BC between 2007 and 2013, include
42 histologically normal tissues; 71 CIS (35 without inva-
sion; 11 associated with microinvasion <0.1 cm; 25 asso-
ciated with invasion >0.1 cm), and 98 IBC (76 invasive
ductal carcinoma (IDC) and 22 invasive lobular carcin-
oma (ILC) as summarized in Table 1. CIS samples, DCIS
and lobular carcinoma in situ (LCIS), were identified
either on diagnostic CNB (65%) or surgical excisions
(35%). Three patients with DCIS diagnosed on CNB had
chemotherapy prior to surgery; for patients with de-
identified tissue samples information on systemic ther-
apy was unavailable. The presence of DCIS was based
on primary diagnosis and verification by the pathologist
(P.J.Z.) prior to cutting slides for analysis. The character-
istics of the analyzed formalin-fixed paraffin-embedded
(FFPE) tumors are presented in accordance with the
REMARK recommendations [18]. Standard prognostic
variables, tumor size, lymph node, grade, as well as hu-
man epidermal growth factor receptor 2 (HER2), estrogen
receptor α (ER) and progesterone receptor (PR) status
from pathology reports are summarized in Table 2. Note,
the erbB-2 immunocytochemical assay was performed on
DCIS and IBC using DakoCytomation (HercepTest) kit.
In this study, tumors positive for ER (ER+), positive or
negative for PR (PR+/−), and negative for HER2 (HER2-)
were classified as ER-positive. Tumors positive for HER2/
ErbB2/neu (3+ in >30% positive cells and/or normal gene
copy number by fluorescence in situ hybridization) were
classified as HER2-positive. A score of 2+ in any portion
of the tumor cells and 3+ in less than 30% of tumor
cells were considered negative/equivocal results. Tu-
mors negative for ER (cutoff <10% positive tumor cells),
Table 2 Clinical characteristics of the study tumor samples
Characteristic Status IBC (%) CIS (%)











Grade (Nottingham score) I 2.0 4.2
II 38.8 43.7
III 46.9 38.0
No report 12.2 14.1
Estrogen Receptor Negative 33.7 32.4
Positive 65.3 67.6
No report 1.0 0.0
Progesterone Receptor Negative 43.9 39.4
Positive 55.1 60.6
No report 1.0 0
HER2/ErbB2/neu Negative/ Equivocal 81.6 69.0
Positive 17.3 21.1
No report 1.0 9.9
Jiang et al. Biomarker Research 2014, 2:22 Page 3 of 9
http://www.biomarkerres.org/content/2/1/22PR (cutoff <10% positive tumor cells), and HER2 (0, 1+,
or 2+ on immunohistochemistry and/or normal gene copy
number by fluorescence in situ hybridization) were classi-
fied as triple negative (TN) breast cancer. A waiver of
written documentation of consent was granted; the Uni-
versity of Pennsylvania Institutional Review Board com-
mittee had approved the analysis of patients’ tissues and
records. The Department of Pathology and Laboratory
Medicine at the University of Pennsylvania provided
CNB containing DCIS. Residual de-identified human
breast tissue was obtained from the University of
Pennsylvania Tumor Tissue and Biospecimen Bank
(TTAB) and the Cooperative Human Tissue Network
(CHTN, Philadelphia, PA).
Immunohistochemistry (IHC)
Methods for IGF-IR and Rap1 IHC staining had been op-
timized [7]. To detect specific proteins, slides were incu-
bated with commercially tested rabbit polyclonal antibody
(Ab) recognizing human IGF-IR β (C-20), Rap1 (121) and
Vav2 (H-200) purchased from Santa Cruz Biotechnology.
The anti- Vav2 Ab was validated in positive/negative hu-
man tissue controls (Additional file 1: Figure S1).Quantitative in tissue protein profiling
To minimize subjectivity of the visual assessment of the in-
tensity of IHC staining and compare the relative protein
expression levels in IHC stained tissues, we used our
imaging-based uniplex (IBU) method previously developed
and validated [7]. The measurements were performed in
the areas of interest following digital tissue segmentation.
The output variable is relative pixel intensity, a ratio calcu-
lated by dividing the mean pixel intensity in tissue area
containing stroma (value ranging from 0 to 65,535) by the
mean pixel intensity of equal area containing cells of inter-
est (value ranging from 0 to 65,535). This computerized
method reduces observer-related bias as calculations of
relative (rather than absolute) intensities of protein staining
minimizes day –to –day fluctuations in IHC results. Mul-
tiple repeated measurements (5 < n < 26) of relative inten-
sity of IHC staining in each tissue sample were analyzed.
Statistical analysis
To compare the differences in protein expression of IGF-
IR, Rap1, and Vav2 among different groups of tissues
including normal, CIS, IBC and combinations of these
groupings, we averaged multiple measurements from each
patient and used one-way ANOVA. Post-hoc t-tests were
performed for pair-wise comparisons among tissue type
groupings and multiple testing corrections were applied
using Tukey’s significance test. We further fitted a repeated
measures mixed effects model over un-aggregated data
with multiple replicates for each patient. A compound sym-
metric covariance structure was specified to account for the
correlation among replicates from each patient. To explore
the correlation between various continuous prognostic vari-
ables and average protein expression of IGF-IR and Rap1,
we computed Pearson’s correlation coefficients. We also fit-
ted univariate logistic regression models using protein ex-
pression of IGF-IR, Rap1, and Vav2 as the continuous
predictors and binary prognostic variables (HER2, ER, PR)
as the dependent variables. Odds ratios (OR) per standard
deviation increase and 95% confidence intervals (95% CI)
were computed. A two-sided significance level of alpha =
0.05 was used for all tests of significance. Receiver operating
characteristic (ROC) curves were used to evaluate how well
each marker predicted DCIS lesion type. Areas under the
curve (AUC) were computed. The modeling process was
verified by cross-validation and the C-Index was computed
as a marker of overall model predictability; together with
95% bootstrap CI. All analyses were carried out in SAS ver-
sion 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Vav2 protein levels increase significantly during the
transition from CIS to IBC
We first compared protein expression profiles in three
histologically different groups of tissue: normal, CIS and
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shown in Figure 1, the levels of expression of all three
proteins were significantly higher in the IBC group com-
pared with the normal group (P <0.0001). Higher levels
of IGF-IR were expressed in the CIS group than in the
normal group (P <0.0001), though levels of IGF-IR protein
expression were similar between the IBC and CIS groups
(P = 0.06). Rap1 protein expression was significantly up-
regulated in the CIS group compared to the normal group
(P <0.0001), and in the IBC group compared to the CISFigure 1 Box plots for unaggregated measurements of IGF-IR,
Rap1, and Vav2 in three major histological groups of tissue:
normal mammary epithelium, CIS and IBC. n, number of samples
per group. +, mean value. Horizontal line, median. Boxes, 25th and
75th percentile. Whiskers, 75th +1.5 x IQR and 25th -1.5 x IQR. Dots,
group outliers. Y axis, protein levels in relative units.group (P = 0.04). In marked contrast, the levels of the
Vav2 protein in the CIS group were similar to that in the
normal group (P = 0.11), whereas significantly higher
levels of Vav2 protein expression were seen in the IBC
group compared to the CIS group (P <0.0001). Thus,
significant up-regulation in IGF-IR and Rap1 expression
may occur as early as in noninvasive CIS, whereas up-
regulation of Vav2 is likely to occur later on during the
transition from CIS to IBC.
High expression of Vav2 in IBC is not associated with
steroid hormone receptors (HR) and HER2 status
We next collected clinical characteristics of our study
tumor samples to address the question of whether in-
creased IGF-IR, Rap1, and Vav2 protein expression in
IBC correlates with standard clinical prognostic factors
(patient’s age, tumor size, grade, and lymph node status,
HR and HER2 status) and to compare with data from
our previously published report [7]. In this study, we
have more than doubled the number of analyzed pri-
mary IBC samples (n = 98 vs. n = 40) and strengthened
our previously reported positive correlation between
Rap1 protein expression and tumor’s size (Pearson’s
ρ = 0.209; pT1-pT4; P =0.04). No correlations were found
between IGF-IR and Vav2 protein levels with the size of
the breast tumors. A statistically significant positive cor-
relation was found between IGF-IR protein expression
and the patient’s age (Pearson’s ρ = 0.242; 28–88 y;
P = 0.04) in IDC, but not in ILC (Pearson’s ρ = −0.007;
32–87 y; P =0.97). Neither Vav2 nor Rap1 protein expres-
sion demonstrated correlation with age at diagnosis of
IBC. We did not find statistically significant correlations
between IGF-IR, Rap1, and Vav2 protein levels with nodal
status or tumor grade. In our cohort of 98 patients
with IBC, we confirmed our earlier findings that higher
expression of Rap1 showed a statistically significant posi-
tive association with both ER and PR positivity (Table 3).
IGF-IR was significantly associated with PR positivityTable 3 Candidate BM association with steroid HR and
HER2 status in IBC
Candidate BM Clinical marker OR 95% P-value
IGF-IR ER 1.44 0.92-2.26 0.11
PR 2.09 1.29-3.38 0.003a
HER2 0.94 0.56-1.56 0.81
Rap1 ER 1.85 1.09-3.17 0.024
PR 1.86 1.14-3.05 0.014
HER2 1.17 0.73-1.89 0.81
Vav2 ER 1.09 0.71-1.67 0.69
PR 1.17 0.78-1.76 0.46
HER2 0.96 0.58-1.60 0.88
aassociations between markers found to be significant are in bold.
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cance was not achieved for the latter (P = 0.11). In
marked contrast, higher levels of Vav2 protein expres-
sion showed no association with ER + and PR + status
in the same group of IBC. There was no association be-
tween HER2 positivity and higher IGF-IR, Rap1, and
Vav2 protein levels. Thus, in contrast to IGF-IR and
Rap1, Vav2 protein expression in IBC does not appear
to be associated with ER and PR status.
Subgroups of DCIS stratified by HR and HER2 statuses have
similar levels of Vav2 protein as histologically normal tissue
Because IBC and CIS include heterogeneous groups of
lesions with diverse morphological and biological fea-
tures, we posited that the changes in each protein’s
expression might evolve differently in different tumor
subtypes. We divided the samples of the IDC and
DCIS groups into more homogeneous subgroups of tu-
mors based on the available status of HR and HER2
(Table 4). We included ER+/PR+/−/HER2 – tumors in
the ER -positive subgroups, ER+/−/PR+/−/HER2+ tumors
in the HER2–positive subgroups and ER-/PR-/HER2-
tumors in the TN subgroups. We omitted ILC and
LCIS samples from further stratification due to small
sample size and/or lack of the information required for
subgrouping. As illustrated in distributional box plots
in Figure 2 and summarized in Table 5, the levels of the
IGF-IR and Rap1 proteins were significantly increased
in the ER- and HER2 –positive subgroups, but not in
the TN subgroup of IDC relative to normal epithelium.
IGF-IR and Rap1 protein levels were also significantly
up regulated in ILC, 95% of which were ER-positive tu-
mors. Remarkably, a statistically significantly higher ex-
pression of Vav2 protein was detected in all tested IDC
and ILC compared with normal tissue, regardless of the
status of ER and HER2 (Figure 2A). In the DCIS sub-
groups, IGF-IR protein levels were significantly increased
in all except in the TN subgroup, whereas Rap1 proteinTable 4 Characteristics of patients and tissue subgroups







DCIS 64 (100%) 55.9 (57) 29-80
DCIS (ER+)a 38 (59.4%) 53.9 (54) 29-80
DCIS (HER2+)b 15 (23.4%) 55.9 (57) 35-69
DCIS (TN)c 11 (17.2%) 62.5 (64) 55-74
IDC 76 (100%) 56.1 (56) 28-88
IDC (ER+)a 38 (50.0%) 57.8 (56) 29-88
IDC (HER2+)b 14 (18.4%) 53.4 (53) 32-88
IDC (TN )c 24 (31.6%) 54.9 (58) 28-77
aER -positive subgroups include ER+/PR+/−/HER2 – tumors; bHER2–positive sub-
groups include ER+/−/PR+/−/HER2+ tumors; c TN subgroups include ER-/PR-/HER2-.levels were significantly increased only in the ER-positive
subgroup (Figure 2B). Most interestingly, pair-wise com-
parisons between normal tissue and DCIS subgroups
showed that there were no statistically significant differ-
ences in Vav2 protein expression among normal tissue
and the subgroups of DCIS stratified based on ER and
HER2 status (Table 5).
Vav2 protein levels increase in DCIS with concurrent
invasion, but not in DCIS without associated invasion
Because Vav2 was increased in IBC, but not in DCIS le-
sions, we hypothesized that change in Vav2 protein ex-
pression might be associated specifically with the onset
of invasive potential in tumor cells, i.e. invasive tumor
progression. If so, Vav2 protein up-regulation could be a
predictor for the development of invasive potential in tu-
mors without morphologic signs of invasion. To test this
hypothesis, we stratified 71 samples of CIS into three
histologically different groups with regard to invasion:
35 DCIS without concurrent invasion (DCIS), 11 DCIS as-
sociated with microinvasive (<0.1 cm) carcinoma (DCIS/
T1mic) and 21DCIS/4LCIS associated with >0.1 cm areas
of invasion (DCIS/IDC + LCIS/ILC). It is worth emphasiz-
ing that our cohort of DCIS samples are patient- matched
cases: DCIS on CNB and subsequent excisions with DCIS
without or with microinvasion. This cohort was selected
on review of a total of 928 records of DCIS on CNB, with
19.7% of matched cases found to be with microinvasion
on subsequent excision, but not on preceding biopsy.
While T1mic was not necessarily present on slides that
were cut freshly from diagnostic blocks for our analysis,
T1mic was documented on CNB or subsequent excision
pathology reports. This stringent criterion of selection of
DCIS vs. DCIS/T1 mic was applied to stratify DCIS sam-
ples, as likely as feasible, into indolent (without invasion)
and progressing (with microinvasion) lesions. More im-
portantly, among those cases we only selected DCIS in
CNB that involved at least 4 ducts in size to ensure ad-
equate DCIS sampling to represent the disease process
and avoid risk of exhausting DCIS tissue for future patient
care use. As illustrated in Figure 3A, in normal tissues and
DCIS, Vav2 expression was associated with the cell mem-
brane. Vav2 protein was detected on the cell membrane
and the cytoplasm in DCIS with invasion and in IDC it-
self. Remarkably, Vav2 levels in the DCIS group were
similar to the normal group (P = 0.99), but were in-
creased in DCIS /T1mic and further significantly in-
creased in DCIS/IDC + LCIS/ILC (P = 0.03). Rather
unexpectedly, compared to normal epithelium, significant
increases in IGF-IR (P = 0.0025) and Rap1 (P = 0.007)
were found in earliest proliferative lesions of DCIS with-
out further changes in DCIS/T1mic and DCIS/IDC +
LCIS/ILC (Figure 3B). The area under the ROC curve in-
dicates low abilities of IGF-IR and Rap1 measurements to
Figure 2 Box plots for unaggregated measurements of IGF-IR, Rap1, and Vav2 in the tissue groups (normal, ILC) and subgroups of IDC
and DCIS. (A) normal mammary epithelium; ER –positive (ER+), HER2 –positive (HER2+), triple negative (TN) IDC, and ILC; (B) normal mammary
epithelium; ER –positive (ER+), HER2 –positive (HER2+), triple negative (TN) DCIS. +, mean value. Horizontal line, median. Boxes, 25th and 75th
percentile. Whiskers, 75th +1.5 x IQR and 25th -1.5 x IQR. Dots, group outliers. Y axis, protein levels in relative units.
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trast, Vav2 measurements distinguished CIS with invasion
from pure DCIS and normal cells (AUC, 0.71; 95% CI
0.59- 0.84). Moreover, patients that had high levels of
Vav2 protein expression in DCIS were more than twice asTable 5 Pair-wise comparison between normal group and
subgroups of IDC, group of ILC and subgroups of DCIS
Groups IGF-IR Rap1 Vav2
Adjusted Adjusted Adjusted
P-value P-value P-value
Normal vs. IDC (ER+) <.0001 <.0001 <.0001
Normal vs. IDC (HER2+) <.0001 <.0001 0.0146
Normal vs. IDC (TN) 0.8900 0.0903 0.0172a
Normal vs. ILC <.0001 <.0001 0.0146
Normal vs. DCIS (ER+) <.0001 <.0001 0.1132
Normal vs. DCIS (HER2+) 0.0002 0.0814 0.5853
Normal vs. DCIS (TN) 0.0835 0.0708 0.7756
adifference between the groups found to be significant are in bold.likely to have concurrent invasion than those with low
levels of Vav2 (OR, 2.42; 95% CI 1.26-4-65; P = 0.008).Discussion
Currently, the most important DCIS factors for clinical
decision-making (size and grade) are not necessarily
dictated by the biology of DCIS. Comprehensive mo-
lecular analyses of DCIS are being limited by the
microscopic size of DCIS lesions, the low availability of
DCIS samples for laboratory research, and the scarcity
of quantitative tools for FFPE tissue examination. In
the present study, we identified DCIS on diagnostic
CNB and surgical excisions, with stratification by ster-
oid HR status, HER2 status, and the presence of con-
current invasion. We then applied our imaging-based
method for direct in-tissue protein quantification,
which allowed us to firstly validate our previous find-
ings regarding IGF-IR and Rap1, and secondarily
characterize the Vav2 protein expression profiles in pa-
tients with breast tumors.
Figure 3 Differential expression of IGF-IR, Rap1, and Vav2 in DCIS, DCIS with microinvasion, DCIS/LCIS with invasion >1 mm. (A)
Representative monochrome images of Vav2 staining in normal mammary epithelium, DCIS, DCIS/T1mic, DCIS/IDC, and IDC. Original magnification
(x200). Insets, enlarged images of epithelial cells. Arrows, suspected microinvasion. (B) Box plots for unaggregated measurements of IGF-IR, Rap1, and
Vav2 in the groups of tissue: normal mammary epithelium, DCIS, DCIS/T1mic, and DCIS/IDC + LCIS/ILC. +, mean value. Horizontal lines, medians. Boxes,
25th and 75th percentile. Whiskers, 75th +1.5 x IQR and 25th -1.5 x IQR. Dots, group outliers. Y axis, protein levels in relative units. (C) The ROC curves for
averaged measurements of IGF-IR, Rap1, and Vav2 protein expression.
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sensitivity to hormone and radiation therapy
In this study, we found that significant up-regulation of
the IGF-IR protein expression occurred much earlierthan previously thought, as early as in DCIS [19,20].
For patients diagnosed with DCIS and undergoing
breast-conserving surgery (BCS), a key decision often is
whether to add tamoxifen and /or radiation therapy
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recurrence.
Studies have shown that IGF-IR signalling is a mechan-
ism of escape from hormone dependence that might pro-
mote tamoxifen resistance in ER – positive BC [21,22].
We determined positive associations between the IGF-IR
and ER/PR in 98 IBC cases, consistently with early find-
ings [19,23]. We also determined a statistically significant
up-regulation of IGF-IR in the ER-positive subgroup of
DCIS, which constitutes 75% of DCIS in general [24] and
59% of DCIS in our study. These novel findings imply that
the assessment of IGF-IR levels along with standardized
cytomorphological criteria may help to predict tumor re-
sponse to tamoxifen and perhaps explain why 8% of
women taking tamoxifen post-BCS, experience DCIS re-
currence or further progression to IBC five years later
[25]. IGF-IR is a key receptor in DNA repair and protec-
tion against apoptosis. Depletion or inhibition of the IGF-
IR has been shown to delay repair of radiation-induced
DNA double-strand breaks, enhance tumor radiation sen-
sitivity and amplify RT-induced apoptosis [26-28]. IGF-IR
overexpression has been related to resistance to radiation
in cell lines and in the clinical setting, making IGF-IR ex-
pression a suitable predictive factor for RT response and
outcomes [29]. IGF-IR overexpression and activation is
also associated with an increased propensity for invasion
and metastasis [30]. These IGF-IR effects are mediated by
multiple signaling intermediates that influence invasive
potential [31]. In this study, we found that both IGF-IR
and Rap1 were up-regulated in ER-positive DCIS and IBC.
These results suggest that IGF-IR-Rap1 signaling may
have a controlling role through the development of most
common ER-positive breast malignancy.
Considering experimental evidence of IGF-IR-associated
resistance to tamoxifen and radiation, our findings war-
rant further clinical studies on IGF-IR as potential predict-
ive BM of sensitivity to the most common treatments
offered to DCIS patients.
Vav2 levels may aid in distinguishing indolent from
progressive DCIS lesions
In contrast to IGF-IR and Rap1, Vav2 protein expression
remained non-elevated in noninvasive proliferative le-
sions found in the mammary gland such as DCIS until
later stages of tumor progression to IBC. To the best of
our knowledge, the present report is the first compre-
hensive study characterizing the clinical relevance of the
Vav2 protein for breast pathogenesis.
Earlier IHC attempts reported no difference in Vav2
staining between BC and normal/hyperplastic mammary
tissue [32], despite ample preclinical studies implicating
oncogenic activation of Vav2 with cancer progression
[33-35]. In this study, we found that DCIS in patients
whose tumor cells invaded into surrounding tissue hadsignificantly increased levels of Vav2 protein expression
compared to those that did not. Of particular interest,
the elevated levels of the Vav2 protein were detected in
DCIS/T1 mic, although concurrent microinvasion was
not necessarily present in the DCIS samples during our
analysis. It has been suggested that DCIS/T1 mic repre-
sents the earliest stage of neoplastic invasion and has a
different biology than pure DCIS, although the molecu-
lar characteristics have not been identified [36].
We demonstrated in this study that in tissue measure-
ments of Vav2 protein expression had discriminating
power allowing for discernment of DCIS from DCIS
with concurrent invasion. Hence, our novel findings sug-
gest that Vav2 may be a companion diagnostic tool cap-
able of predicting the likelihood of microinvasion that
otherwise can be over- and under- diagnosed because of
limitations with tissue sampling. Furthermore, Vav2 has
been deemed a promising target for cancer therapy, with
small molecule compounds being developed that specif-
ically target Vav2 activity in cancer [37].
Conclusions
This study describes the use of a novel imaging method
for archival tissue testing, which may inform the status of
protein BM in tumor and may help to stratify a women’s
individual risk for tumor invasiveness to avoid potential
over- or under-treatment. Despite the apparent limitation
of our study DCIS cohort size, our novel findings on Vav2
hold promise for utilizing Vav2 protein as a BM of progres-
sive DCIS and a target for cancer therapy.
Additional file
Additional file 1: Figure S1. Vav2 staining in positive (skin, placenta)
and negative (lymph node) human tissue controls. Fresh 5 μm sections
were cut from FFPE tissue blocks, de-paraffinized in xylene, rinsed in
ethanol, and re-hydrated. Antigen was heat-retrieved in 10 mM Na
citrate, pH6.0; endogenous peroxidase was quenched by pretreatment
with 1.0% H2O2. Incubating with 5% goat serum minimized nonspecific
staining. To detect specific protein, slides were incubated overnight at
4°C with commercially tested rabbit polyclonal Ab recognizing human
Vav2 (H-200) purchased from Santa Cruz Biotechnology. A biotinylated
goat anti-rabbit secondary Ab was used for detection bound primary Ab
and as an isotype-matched negative control. Staining was developed for
4 min using the VECTASTAIN Elite ABC and the VECTOR VIP substrate kits
(Vector Labs). Time of the development was optimized to avoid VIP
saturation. Original magnification (x200). Arrows, examples of positively
and negatively stained cells. Similar to the findings reported by the Swedish
Human Protein Atlas Program (http:www.proteinatlas.org), the cells in lymph
nodes were completely negative for Vav2 protein, whereas cells in the skin
basal epidermal layer (stratum basale) and migratory trophoblasts in the
placenta were intensely stained.
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